2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2305

Peripheral Arterial Disease Is Associated with an Increased Risk of Subsequent Hip Fracture: A Systematic Review and Meta-Analysis of Cohort Studies

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2732

Peripheral Neuropathy Is More Common in Microscopic Polyangiitis Than in Granulomatosis with Polyangiitis: Data from a Single Tertiary Referral Center

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 2354

Perspectives of Patients with Inflammatory Arthritis Regarding Cardiovascular Risk: A Qualitative Study

Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

9:00AM-11:00AM: Abstract Number: 2338

Pharmacological and Non-Pharmacological Approaches in a Group of Osteoporotic Patients Referring to a Rehabilitation out-Patient Clinic

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster – ARHP

9:00AM-11:00AM: Abstract Number: 2383

Pharmacovigilance of Biologics for Non-Systemic Juvenile Idiopathic Arthritis By the German Biologics Registry

Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

9:00AM-11:00AM: Abstract Number: 2550

Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 1963

Phenome Wide Association Study of IL6R Variant Identifies Drug Target for Cardiovascular Disease and Inflammation

Genetics, Genomics and Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2710

Physical Activity Trackers Work Well As a Monitor of Physical Activity in Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2370

Physician and Patient Preferences for Treating SLE: Insights into the Choice of Intravenous Infusion and Subcutaneous Injection

Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

9:00AM-11:00AM: Abstract Number: 2479

Pilot Study of Characterizing Rheumatoid Arthritis Related Morning Stiffness

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2080

Plasmatic Glycoprotein and Lipoprotein Nuclear Magnetic Resonance Profiles Associated with Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1971

PLCG2 Variants Influence CVID Susceptibility: Expanding the Spectrum of PLCG2-Associated Immune Dysregulation

Genetics, Genomics and Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2125

Pleiotropy of a Positive Antinuclear Antibody (ANA) Test: A Phewas and GWAS Approach

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2686

Podocyte Foot Process Width Is a Prediction Marker for Complete Renal Remission at 6 and 12 Months after Induction Therapy in Lupus Nephritis

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2179

Poor Rates of Screening for Retinal Toxicity in Patients on Antimalarial Medications: A Population-Based Study

Health Services Research Poster III – ACR/ARHP

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].